Metabonomics Study of Chronic Gastritis and Gastric Carcinoma

Overview

The pathogenetic mechanisms of chronic gastritis and gastric carcinoma are different. Whether metabonomics play a role in the development of chronic gastritis and gastric cancer is still a question. So the investigators want to clarify this question by this subject.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: April 30, 2021

Detailed Description

This project was an untargeted metabolomics study using liquid chromatography coupled with mass spectrometry (LC-MS) in patients with chronic gastritis and gastric carcinoma. The experimental procedures mainly include sample collection, metabolite extraction, LC-MS/MS detection, data analysis, etc.The goal of this study is to identify and (relatively) quantify as many metabolites in biological systems as possible, so as to reveal the overall metabolite information to the maximum extent. Metabolomics aims to investigate the changes of metabolites in gastric tissues in patients with chronic gastritis and gastric carcinoma, and to study the biological processes in which these metabolites participate by screening the different metabolites in the different groups, and to reveal the mechanism of life activities in which they involved in.

Interventions

  • Diagnostic Test: different diseases
    • Patients will be divided into three groups, including chronic superficial gastritis ,chronic atrophic gastritis and gastric carcinoma.

Arms, Groups and Cohorts

  • Patients with chronic superficial gastritis
    • Patients with chronic superficial gastritis
  • Patients with chronic atrophic gastritis
    • Patients with chronic atrophic gastritis
  • Patients with gastric carcinoma
    • Patients with gastric carcinoma

Clinical Trial Outcome Measures

Primary Measures

  • Metabonomic difference in patients with chronic gastritis and gastric carcinoma
    • Time Frame: six months
    • 1.The different levels of metabolites in gastric tissues in patients with chronic gastritis and gastric carcinoma. 2. The common change model of metabolites in gastric carcionoma compared with chronic gastritis.

Secondary Measures

  • Association of different metabolic substances and disease results in chronic gastritis and gastric carcinoma
    • Time Frame: six months
    • The researchers want to reveal the relationship between different metabolic sustances and disease result in patientswith chronic gastritis and gastric carcinoma.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with chronic superficial gastritis and chronic atrophic gastritis – Patients with gastric carcinoma Exclusion Criteria:

  • Patients with history of surgery – Patients with severe heart disease,lung disease or kidney disease.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Second Affiliated Hospital, School of Medicine, Zhejiang University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Hanyuehua, Chief physician – Second Affiliated Hospital, School of Medicine, Zhejiang University
  • Overall Official(s)
    • Yuehua Han, Dr., Principal Investigator, 2nd Affiliated Hospital, School of Medicine, Zhejiang university, China
  • Overall Contact(s)
    • Yuehua Han, Dr., +86 13858126927, 13858126927@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.